Celcuity Inc (CELC) Stock Price, Quote & News

Company Profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 neg...

Industry: Biotechnology

Sector: Healthcare

Phone: (763) 392-0767

Website: www.celcuity.com

Address:

16305 36th Avenue North, Suite 100, Minneapolis, United States

woodstockery Aug. 22 at 11:34 AM

$CELC above 52w high in premarket.

0 · Reply

taylord0711 Aug. 21 at 6:17 PM

$CELC LMFAOOOO

0 · Reply

kshonstocks Aug. 21 at 1:38 PM

Wd love to see $CELC recover 9 dma near 50

0 · Reply

kshonstocks Aug. 21 at 12:01 AM

$CELC big buyer last 15 mins pre close

0 · Reply

Trmpt Aug. 20 at 7:24 PM

$BTAI $CELC

0 · Reply

ahk17 Aug. 20 at 7:22 PM

$BTAI $CELC had the same scenerio. People were selling for loss right before data readout and after the data readout it went 250% up. Don't regret later. Buy and hold. This is your chance to make money. Ignore all the bears!!

0 · Reply

Pipelinepivots Aug. 20 at 4:06 AM

🚨🚨TGL this one can be the next life changer like SBET BMNR, Micro float, with billion dollar reach and a tiny market cap and a 100m treasury! $20+ POTENTIAL! $IPA $OPEN $SY $CELC ....

1 · Reply

Easternbikes5 Aug. 19 at 6:12 PM

$CELC

0 · Reply

kshonstocks Aug. 19 at 3:36 PM

$CELC near 9 dma shd be good buying spot

0 · Reply

ebk81 Aug. 18 at 4:21 PM

$CELC Massive gap to close @ $15! no rev projected until at least Q3-4 of 2026. yeas they have the cash to operate but to get these drugs to market *if they are successful and FDA approved it will require more capital then what will be left

1 · Reply

Celcuity Inc. (CELC) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 4:01 PM EDT - 7 days ago

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 7:05 AM EDT - 15 days ago

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Jul 30, 2025, 3:42 PM EDT - 22 days ago

Celcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 Catalyst

Jul 30, 2025, 6:30 AM EDT - 23 days ago

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants

Jul 29, 2025, 6:40 AM EDT - 24 days ago

Celcuity: What's Happening With CELC Stock?

Jul 28, 2025, 4:02 PM EDT - 24 days ago

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Jul 28, 2025, 3:02 PM EDT - 24 days ago

Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success

Jul 28, 2025, 7:49 AM EDT - 25 days ago

Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study

Jul 28, 2025, 7:00 AM EDT - 25 days ago

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

Jul 25, 2025, 4:05 PM EDT - 27 days ago

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Jul 24, 2025, 4:01 PM EDT - 4 weeks ago

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Jul 14, 2025, 7:05 AM EDT - 5 weeks ago

Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042

Jun 30, 2025, 7:05 AM EDT - 7 weeks ago

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

May 21, 2025, 7:05 AM EDT - 3 months ago

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

May 14, 2025, 9:36 PM EDT - 3 months ago

Celcuity Inc. (CELC) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:01 PM EDT - 3 months ago

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 7:05 AM EDT - 3 months ago

Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

Apr 1, 2025, 7:05 AM EDT - 5 months ago

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Mar 31, 2025, 10:50 PM EDT - 5 months ago

Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:01 PM EDT - 5 months ago

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:05 AM EDT - 5 months ago

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

Feb 25, 2025, 7:05 AM EST - 6 months ago

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

Feb 19, 2025, 6:24 PM EST - 6 months ago

Celcuity's High-Stakes Oncology Bet Is Underappreciated

Dec 11, 2024, 7:05 AM EST - 9 months ago

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

Nov 14, 2024, 7:42 PM EST - 10 months ago

Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:01 PM EST - 10 months ago

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

Nov 12, 2024, 7:05 AM EST - 10 months ago

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

Nov 7, 2024, 7:05 AM EST - 10 months ago

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

Aug 16, 2024, 3:50 PM EDT - 1 year ago

Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

Aug 7, 2024, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call

Jul 5, 2024, 12:05 AM EDT - 1 year ago

Celcuity: Flying A Phase 3 Trial Right Under Your Nose

Jun 3, 2024, 4:01 PM EDT - 1 year ago

Celcuity To Participate in Jefferies Global Healthcare Conference

May 30, 2024, 7:36 AM EDT - 1 year ago

Celcuity Announces Pricing of Underwritten Common Stock Offering

May 30, 2024, 7:00 AM EDT - 1 year ago

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

May 15, 2024, 7:43 PM EDT - 1 year ago

Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:01 PM EDT - 1 year ago

Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update

May 8, 2024, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call

Mar 27, 2024, 6:40 PM EDT - 1 year ago

Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 20, 2024, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

Mar 6, 2024, 7:05 AM EST - 1 year ago

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

Feb 28, 2024, 7:05 AM EST - 1 year ago

Celcuity to Participate in Cowen's 44th Annual Health Care Conference

Feb 20, 2024, 7:05 AM EST - 1 year ago

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

Dec 6, 2023, 8:30 AM EST - 1 year ago

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

Dec 1, 2023, 11:02 AM EST - 1 year ago

Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium

Nov 22, 2023, 8:05 AM EST - 1 year ago

Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 13, 2023, 12:41 PM EST - 1 year ago

Celcuity Inc. (CELC) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:05 AM EST - 1 year ago

Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

woodstockery Aug. 22 at 11:34 AM

$CELC above 52w high in premarket.

0 · Reply

taylord0711 Aug. 21 at 6:17 PM

$CELC LMFAOOOO

0 · Reply

kshonstocks Aug. 21 at 1:38 PM

Wd love to see $CELC recover 9 dma near 50

0 · Reply

kshonstocks Aug. 21 at 12:01 AM

$CELC big buyer last 15 mins pre close

0 · Reply

Trmpt Aug. 20 at 7:24 PM

$BTAI $CELC

0 · Reply

ahk17 Aug. 20 at 7:22 PM

0 · Reply

Pipelinepivots Aug. 20 at 4:06 AM

🚨🚨TGL this one can be the next life changer like SBET BMNR, Micro float, with billion dollar reach and a tiny market cap and a 100m treasury! $20+ POTENTIAL! $IPA $OPEN $SY $CELC ....

1 · Reply

Easternbikes5 Aug. 19 at 6:12 PM

$CELC

0 · Reply

kshonstocks Aug. 19 at 3:36 PM

$CELC near 9 dma shd be good buying spot

0 · Reply

ebk81 Aug. 18 at 4:21 PM

1 · Reply

Quantis Aug. 18 at 3:54 PM

$LGVN: Roth Capital cuts target to $3 from $10, citing dilution and Q2 results. From biotech hope to biotech nope. $BMEA: H.C. Wainwright slashes target to $4 from $18, maintaining a Buy rating. Dilution concerns overshadow diabetes and obesity programs. $LODE: Analysts slash outlook to $4 as dilution reigns supreme. More shares, less value… and the moon keeps moving further away. $CELC: Needham lowers target to $70 from $74, citing dilution concerns. Oncology dreams diluted by capital raises. $LULU: JPMorgan downgrades to Neutral with a $224 target, citing high valuation and slowing growth. Athleisure dreams on a treadmill.

0 · Reply

Quantumup Aug. 18 at 12:28 PM

H.C. Wainwright⬆️ $CELC's PT to $66 from $50, reit'd Buy and and said that recent 'Topline Data From The WT Cohort Are Very Supportive Of FDA Approval' after Celcuity reported 2Q25 financial and operating results. $AZN $PFE $RHHBY $NVS ARVN LLY H.C. Wainwright said in its note: Management confirmed that the company plans to submit a new drug application (NDA) by year-end based on data from the PIK3CA wild-type (WT) cohort of the Phase 3 VIKTORIA-1 study of gedatolisib + fulvestrant At palbociclib for treatment of HR+/HER2- advanced breast cancer in CDK4/6-pretreated patients. We believe the recently disclosed topline data from the WT cohort are very supportive of FDA approval. If successful, the drug could receive marketing approval by mid-2026. H.C. Wainwright additionally said:

0 · Reply

JarvisFlow Aug. 18 at 11:00 AM

HC Wainwright & Co. has updated their rating for Celcuity ( $CELC ) to Buy with a price target of 66.

0 · Reply

SophieSS Aug. 17 at 9:41 PM

$CELC The most important thing when investing in stocks is the company's profitability and long-term value. I don't see the value here.

1 · Reply

d_risk Aug. 17 at 5:19 AM

$CELC - Celcuity Inc. Common Stock - 10Q - Updated Risk Factors CELC flags new risks from shifting trade policies and tariffs that could raise costs and disrupt supply chains, plus warns that FDA or other regulatory agency disruptions could delay product approvals and hurt business. #Biotechnology #TariffImpact #TradePolicy #SupplyChainDisruption #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/CELC/10-Q/2025-08-14

0 · Reply

Quantumup Aug. 15 at 4:22 PM

Stifel⬆️the PT on $CELC to $68 from $65 and keeps at a Buy rating. $AZN $PFE $RHHBY $NVS ARVN LLY Stifel said in its note to investors:

0 · Reply

Florestan Aug. 15 at 3:34 PM

$CELC it must be tough to be this stupid.

0 · Reply

Quantumup Aug. 15 at 12:03 PM

Jefferies⬆️ $CELC $79 Needham⬇️ $CELC $70 Jefferies: Following the unprecedented PFS data from the ph.IIl study in 2L PIK3CAwt HR+ HER2- aBC, stock has surged substantially (+277%). However, we believe additional upside pot'l remains, w/ the data from the PIK3CAmut ph.IlI expected 4Q25 and pot'l approval in WT likely in 2026, following NDA filing in 4Q25. Add'ly, co plans to present results from the WT ph.Ill at an upcoming med mtg, which could further de-risk the story. Raising PT to $79 (+$25). Needham: Celcuity reported 2Q:25 financial results yesterday. The company remains on track to submit an NDA for gedatolisib (geda) in PIK3CA wild-type mBC in 4Q:25 after reporting positive topline results from the pivotal VIKTORIA-1 study in July (note). Pivotal PIK3CA mutant results remain guided for 4Q:25 and are the next key driver for $CELC. We are positively biased on the upcoming readout, given results in WT. We maintain our Buy Rating but are lowering our Target to $70 adjusting for dilution.

0 · Reply

bulldogs54 Aug. 15 at 10:37 AM

$CELC "Potential Dilution (if it's a secondary offering): If the offering involves creating new shares (dilutive), it can decrease the earnings per share and may negatively impact the stock price." - Well then wtf are we doing then? Just sitting there with our thumbs up our butts?

1 · Reply

bulldogs54 Aug. 15 at 10:34 AM

$CELC I'm no longer in a position here, but when you have a speculative stock that gaps up 300% and keeps going up 3% a day even with terrible earnings, you know the market is in a bubble. You can't make this shit up

1 · Reply

JarvisFlow Aug. 15 at 10:30 AM

Needham has adjusted their stance on Celcuity ( $CELC ), setting the rating to Buy with a target price of 74 → 70.

0 · Reply

Geo0240 Aug. 15 at 4:22 AM

$CELC I’m short 2 shares…not fucking covering. 😈

1 · Reply

Market Cap	2.09B
Revenue (ttm)	0.00
Net Income (ttm)	-111.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	2.24

Volume	1,362,700
Avg Vol	1,338,238
Day's Range	N/A - N/A
Shares Out	42.43M
Stochastic %K	60%
Beta	0.68
Analysts	Strong Sell
Price Target	$69.43